ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment

E. Bouman-Wammes, J. M. van Dodewaard-De Jong, H. Bloemendal, H. M. Verheul, J. M.H. de Klerk, A. J.M. van den Eertwegh

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)viii302
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - 1 Oct 2018

Cite this